ALKBH5 and acute myeloid leukemia: ALKBH5 downregulates P21 and upregulates MYC protein levels by modulating TACC3 mRNA stability, thereby promoting AML cell proliferation and LSC self‐renewal, which is associated with poor outcomes in AML patients.